<Suppliers Price>

ACT-451840

Names

[ CAS No. ]:
1984890-99-4

[ Name ]:
ACT-451840

[Synonym ]:
(2E)-N-[4-(4-Acetyl-1-piperazinyl)benzyl]-N-{(2S)-1-[4-(4-cyanobenzyl)-1-piperazinyl]-1-oxo-3-phenyl-2-propanyl}-3-[4-(2-methyl-2-propanyl)phenyl]acrylamide
2-Propenamide, N-[[4-(4-acetyl-1-piperazinyl)phenyl]methyl]-N-[(1S)-2-[4-[(4-cyanophenyl)methyl]-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-3-[4-(1,1-dimethylethyl)phenyl]-, (2E)-
ACT-451840
MFCD31700747

Biological Activity

[Description]:

ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial[1][2][3].

[Related Catalog]:

Research Areas >> Infection

[In Vitro]

ACT-451840 shows a 50 % inhibition concentration of 0.4 nM against the drug-sensitive P. falciparum NF54 strain. The IC50 value of ACT-451840 against the murine malaria parasite P. berghei is 13.5 nM in in vitro ex vivo assays.

[In Vivo]

ACT-451840 (10 and 60 mg kg) starts to show significant antimalarial effects (parasite reduction) in vivo at 20 mg/kg. ACT-451840 exhibits curative activity at 300 mg/kg and significant antimalarial effects already at 100 mg/kg. ACT-451840 shows excellent reduction at 30 mg/kg, resulting in 99.80 % activity[2]. ACT-451840 shows efficacy in the Plasmodium berghei mouse model[2].

[References]

[1]. Bruderer S, et al. First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. Antimicrob Agents Chemother. 2015;59(2):935-942.

[2]. Boss C, et al. Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action. ChemMedChem. 2016;11(18):1995-2014.

[3]. Le Bihan A, et al. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. PLoS Med. 2016;13(10):e1002138. Published 2016 Oct 4.

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
953.8±65.0 °C at 760 mmHg

[ Molecular Formula ]:
C47H54N6O3

[ Molecular Weight ]:
750.97

[ Flash Point ]:
530.6±34.3 °C

[ Exact Mass ]:
750.425720

[ LogP ]:
6.74

[ Vapour Pressure ]:
0.0±0.3 mmHg at 25°C

[ Index of Refraction ]:
1.652

Related Compounds